SCHEMBL6897911

SCHEMBL6897911

Cc1ccccc1C1(C#N)C2CC3CC(C2)CC1C3

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
SIGMAR1 Q99720 4/20 0.33
TSHR P16473 1/20 0.33
HSD11B1 P28845 4/20 0.33
P2RX7 Q99572 2/20 0.33
GRIN2B Q13224 2/20 0.31
HDAC4 P56524 1/20 0.31
OPRM1 P35372 1/20 0.30
GRIN2D O15399 1/20 0.30
GRIN3B O60391 1/20 0.30
GRIN1 Q05586 1/20 0.30
GRIN2A Q12879 1/20 0.30
GRIN2C Q14957 1/20 0.30
GRIN3A Q8TCU5 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL790543 0.80 SIGMAR1 (0.37) SIGMAR1TSHRHSD11B1P2RX7GRIN2B
SCHEMBL6895186 0.75 HSD11B1 (0.45) SIGMAR1HSD11B1GRIN2BOPRM1GRIN2D
SCHEMBL6897685 0.74 HSD11B1 (0.38) SIGMAR1HSD11B1P2RX7GRIN2BHDAC4
SCHEMBL6680140 0.72 HSD11B1 (0.46) ALDH1A1HSD11B1OPRM1
SCHEMBL6893766 0.71 HSD11B1 (0.42) HSD11B1HDAC4
SCHEMBL7081965 0.70 HSD11B1 (0.34) ALDH1A1SIGMAR1TSHRHSD11B1P2RX7
Hydrochloric Acid SCHEMBL6899621 0.69 HSD11B1 (0.40) SIGMAR1HSD11B1P2RX7GRIN2BGRIN2D
SCHEMBL6686003 0.68 HSD11B1 (0.40) SIGMAR1HSD11B1P2RX7GRIN2BGRIN2D
SCHEMBL6933296 0.68 SIGMAR1 (0.37) SIGMAR1HSD11B1P2RX7GRIN2BHDAC4
SCHEMBL9721521 0.67 HSD11B1 (0.42) ALDH1A1MAPTSIGMAR1TSHRHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1143964-B1 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION VERNALIS RES LTD (GB) 2004-03-24 EP disclosed
EP-1051392-B1 ADAMANTANECARBOXIMIDAMIDE DERIVATIVES AND THEIR USE AS NMDA ANTAGONISTS VERNALIS RES LTD (GB) 2003-12-17 EP disclosed
WO-2003064372-A1 2-ADAMANTYLALKYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION VERNALIS RESEARCH LIMITED (GB) 2003-08-07 WO disclosed
US-6531511-B1 N-methyl aspartate receptor antagonist VERNALIS RESEARCH LIMITED (GB) 2003-03-11 US disclosed
EP-1143964-A1 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION VERNALIS RESEARCH LIMITED (GB) 2001-10-17 EP disclosed
US-6262106-B1 Adamantanecarboximidamide derivatives and their use as NMDA antagonists VERNALIS RESEARCH LIMITED (GB) 2001-07-17 US disclosed
EP-1051392-A1 ADAMANTANECARBOXIMIDAMIDE DERIVATIVES AND THEIR USE AS NMDA ANTAGONISTS VERNALIS RESEARCH LIMITED (GB) 2000-11-15 EP disclosed
WO-2000044371-A1 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION VERNALIS RESEARCH LIMITED (GB) 2000-08-03 WO disclosed
WO-1999038841-A1 ADAMANTANECARBOXIMIDAMIDE DERIVATIVES AND THEIR USE AS NMDA ANTAGONISTS VERNALIS RESEARCH LIMITED (GB) 1999-08-05 WO disclosed